Takeda Pharmaceutical Company Limited (NYSE:TAK) Holdings Raised by Hudson Bay Capital Management LP

Hudson Bay Capital Management LP lifted its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 10.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 275,000 shares of the company's stock after purchasing an additional 25,000 shares during the quarter. Hudson Bay Capital Management LP's holdings in Takeda Pharmaceutical were worth $3,641,000 as of its most recent filing with the Securities & Exchange Commission.Get Takeda Pharmaceutical alerts:Analysts Predict 85% Upside for Wave Life Sciences After Rate CutA number of other institutional investors have also recently bought and sold shares of the stock. Farther Finance Advisors LLC boosted its holdings in shares of Takeda Pharmaceutical by 123.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after buying an additional 1,976 shares during the period. Crowley Wealth Management Inc. acquired a new position in Takeda Pharmaceutical in the 4th quarter worth approximately $52,000. Cromwell Holdings LLC acquired a new position in Takeda Pharmaceutical in the 4th quarter worth approximately $61,000. Venturi Wealth Management LLC grew its position in Takeda Pharmaceutical by 554.7% during the 4th quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company's stock worth $67,000 after purchasing an additional 4,260 shares in the last quarter. Finally, Lindbrook Capital LLC raised its stake in Takeda Pharmaceutical by 65.0% during the 4th quarter. Lindbrook Capital LLC now owns 5,151 shares of the company's stock valued at $68,000 after purchasing an additional 2,029 shares during the period. Hedge funds and other institutional investors own 9.17% of the company's stock. Takeda Pharmaceutical Trading Down 1.4%Shares of NYSE TAK opened at $14.17 on Tuesday. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. Takeda Pharmaceutical Company Limited has a one year low of $12.58 and a one year high of $15.43. The business has a 50-day moving average price of $14.86 and a two-hundred day moving average price of $14.00. The firm has a market capitalization of $45.07 billion, a PE ratio of 35.41, a PEG ratio of 0.24 and a beta of 0.26. Time to buy these 3 healthcare companies that raised revenue guidance?Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. The company had revenue of $7.34 billion for the quarter, compared to analyst estimates of $8.02 billion. As a group, analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year. Wall Street Analyst Weigh InSeparately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.Price Growth & Yield: For That Magical Combo, Leave the U.S.View Our Latest Stock Report on Takeda PharmaceuticalTakeda Pharmaceutical Company Profile (Free Report)Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.See AlsoFive stocks we like better than Takeda PharmaceuticalPros And Cons Of Monthly Dividend StocksPalantir’s Latest Deal Could Put a Freeze on Its Stock PriceTrading Stocks: RSI and Why it's Useful4 Automaker Stocks React to Tariffs: Winners and LosersWhat Investors Must Know About Over-the-Counter (OTC) StocksHere's Why Call Option Traders Love Dutch Bros Stock This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Takeda Pharmaceutical Right Now?Before you consider Takeda Pharmaceutical, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.While Takeda Pharmaceutical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here